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Introduction: Cutaneous malignant melanoma in situ (MIS) has not
been subject to much attention or investigation. Little is known of
the characteristics of patients and tumours. The aim of this study
was to elucidate important tumour characteristics in patients
treated for MIS.
Methods: Based on data from the Danish Melanoma Register, pa-
tient and tumour characteristics were evaluated in a cross-
sectional study including all patients diagnosed with cutaneous
malignant melanoma in Health care Region Zealand between 2012
and 2013.
Results: A total of 144 patients were identiﬁed with malignant
melanoma in situ; more females were affected than males, and
the males were older than females. Patients with lentigo maligna
were older than patients with superﬁcial spreading MIS, which
were predominantly found in the head and neck region. Among
patients treated for MIS, 28% were previously treated for other skin
malignancies.
Conclusion: The anatomical distribution of MIS differed with
patient age and tumour subtype. The anatomical distribution was
different in comparison to invasive malignant melanomas, anduted: Department of Plastic Surgery, Roskilde University Hospital, Roskilde,
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ry, May 2015.
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A. Klit et al. / JPRAS Open 6 (2015) 59e6660MIS cases were generally older. This suggests a non-linear relation
between malignant melanoma in situ and invasive malignant
melanoma.
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Cutaneous malignant melanoma in situ (MIS) is thought to be a precursor to invasive cutaneous
malignant melanoma (CMM).1 However, all MISs may not progress to CMM.2 In Denmark, MIS is
treated according to guidelines from the DanishMelanoma Group,3 which implies local radical excision
at 5-mmdistances to the tumour, and a profound resection of a superﬁcial part of the subcutaneous fat,
ensuring complete removal of the dermis in the affected area.
Patients withMIS have an increased risk of developing a subsequent MIS.4 In addition, they have 4.6
times increased risk of developing subsequent invasive CMM compared with the general population.
An annual increase in the MIS incidence rates of up to 15% has been reported4e8 in Australia, USA and
Sweden. The highest incidence rates of CMM in Europe are found in Northern and Western countries
(Scandinavian countries, the Netherlands, UK and Ireland) and the lowest incidence rates have been
observed in Spain and Portugal.9 World Health Organisation (WHO) Globocan reports that the Danish
female population has the third highest risk of melanoma in the world (First is New Zealand, with
Australia in the second place), and the Danish female population aged 15e39 years had the highest
incidence of CMM in the world.10 In 2006, Denmark showed the highest incidence rates across Europe
(both genders), and different studies have suggested a continuous annual increase in the incidence rate
of more than 3%.11,12 Whereas CMM only represents approximately 4% of all skin cancers, the disease is
responsible for approximately 80% of all skin cancer-related deaths.13
Over the years, the people of Denmark have changed from a culture of avoiding the sun to seeking it
instead. Furthermore, during the 1960s, artiﬁcial sun devices were introduced in Denmark, and a cross-
sectional study by Køster et al in 2009 showed that 29% of all Danes aged 15e59 had used sunbeds
within the past 12 months. Among female children and adolescents aged 15e19 years, 59% had used
sunbeds within the past 12 months.14 As a consequence of the altered sun exposure pattern, in
addition, we hypothesize that the patient and tumour characteristic may have changed during the past
decades. In order to improve targeted examination and intervention, the main aim of this study was to
describe patient and tumour characteristics in a cohort of Danish MIS.
Method
Study design and setting
This was a cross-sectional study based on the entire population living in the Health care Region
Zealand (approximately 800,000 inhabitants) in Denmark. Data were obtained from the national
Danish Melanoma Registry (DMR), which holds prospectively collected information on patients
diagnosedwithMIS or CMM in Denmark.3 Reporting to DMR ismandatory for all departments involved
in the diagnosis and treatment of malignant melanoma. The recorded data include speciﬁc information
on disease characteristics, treatment and follow-up. Patients are registered in DMR after a histological
conﬁrmation of the MIS.
Participants
This study included patients diagnosed with primary MIS between January 2012 and December
2013, residing in the Health care Region Zealand (a governmental administration unit comprising the
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total population of approximately 810,000 inhabitants corresponding to 14% of the entire Danish
population (2013)). The study excluded patients with unknown tumour thickness and Clark level due
to limitations in biopsy material and patients with otherwise incomplete set of data who could not be
supplemented from the patient records.
Variables
The histological examination was conducted at the Department of Pathology, Roskilde University
Hospital, which is a highly specialized facility investigating all melanocytic tumour biopsies from
Region Zealand. All patients were treated at the Department of Plastic Surgery, Roskilde University
Hospital, which is a centralized and highly specialized facility treating all patients in the Region Zea-
land suspected or diagnosed with melanoma.
We obtained data on patient characteristics (gender, age), anatomical tumour location and tumour
characteristics. In addition, we supplemented the data with information on previous malignant tu-
mours from the national Danish Pathology Registry (DPR), which holds information on all pathological
examinations in Denmark. Although it contains some information from as early as 1970, reporting to
DPR has been mandatory since 1997.15
Statistics
Number and proportions were used to describe patient and tumour characteristics. In variables
that were not normally distributed, median values were used with minimum and maximum values.
Non-parametric ManneWhitney statistical test was used to test for difference in these cases. Differ-
ences in tumour site, age groups, MIS tumour type and other skin cancer types were tested using chi-
squared test (Fischer's exact). Level of signiﬁcance was set at p ¼ 0.05. All statistical methods were
computed using the dedicated statistical software InStat (version 3) and Prism (version 5), GraphPad,
USA.
Results
Participants
A total of 151 patients of MIS were identiﬁed. Seven patients were duplets and subsequently
excluded as only the ﬁrst MIS of each patient was used in the following comparative analysis. A total of
144 patients with MIS (Clark level 1) were thus included in this study (Table 1).Table 1
Patient and tumour characteristics in 144 patients diagnosed with cutaneous malignant melanoma in situ.
Total Female Male p-value
Number (%) 144 (100) 78 (54) 66 (46)
Median age (range) (years) 66 (26; 98) 63 (26; 98) 68 (28; 89) <0.05
Tumour site (no, %)
Head and neck 59 (41) 29 (37) 30 (45) 0.08
Trunk 38 (26) 17 (22) 21 (32)
Upper extremities 19 (13) 11 (14) 8 (12)
Lower extremities 22 (15) 17 (22) 5 (8)
Not available 6 (4) 4 (5) 2 (3)
Tumour type (no, %)
Superﬁcial spreading 80 (56) 45 (58) 35 (53) 0.32
Acral lentiginous 2 (1) 2 (3) 0 (0)
Lentigo maligna 62 (43) 31 (40) 31 (47)
Nodular 0 (0) 0 (0) 0 (0)
Not available 0 (0) 0 (0) 0 (0)
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Of the 144 patients included for analysis, 78 (54%) were female and 66 (46%) were male patients.
Overall median age was 66 years (median age; males: 68 years vs. females: 63 years, p < 0.05).
Both genders hadMIS predominantly localized in the head and neck region (41% of all MIS) followed
by trunk (26% of all MIS). There was no statistical difference in anatomic localization between the
genders, p ¼ 0.08. Of the 144 MIS, superﬁcial spreading malignant melanoma (SSM) in situ accounted
for 56%, lentigo maligna (LM) 43% and acral lentiginous melanoma (ALM) in situ 1%, respectively. There
was no statistically signiﬁcant difference between the genders, p ¼ 0.32.
We found the median age to be signiﬁcantly higher among patients with LM in comparison to SSM
in situe 71 years (range: 46e98) versus 59 years (range: 26e93), respectively, p < 0.001. We compared
the anatomical localization between age groups (age <21 years (n ¼ 0), 21e40 years (n ¼ 8), 41e60
years (n ¼ 39), 61e80 years (n ¼ 81) and >80 years (n ¼ 16)) and found a signiﬁcant difference in
anatomical distribution between the age groups, p > 0.001 (Figure 1). While 49% of the tumours in the
age group ‘61e80 years’ were located in the head and neck region, the ‘>80 years’ age group had 75% of
the tumours located in the head and neck region. In contrast, the ‘41e60 years’ age group had tumours
located on the trunk (46%), with 13% located in the head and neck region. We compared the anatomical
localization of LM (n ¼ 61, one missing data on tumour localization) and SSM in situ (n ¼ 75, ﬁve
missing data on tumour localization) and found an overall signiﬁcant difference in the anatomical
distribution (p < 0.001) as patients diagnosed with LM, 82% were located in the head and neck region
and only 3%were located on the trunk. In comparison, 48% of SMM in situ were found on the trunk, and
22% were found in the head and neck region.
Furthermore, we investigated the historic prevalence of previous skin cancer and actinic keratosis
(considered to be a precursor for squamous cell cancer) in the patients' data retrieved from the Danish
Registry of Pathology. Among the 144 patients diagnosed with MIS, we found 41 (28%) with prior (all
time) one or more malignant skin tumour type (no difference was found between genders; p ¼ 0.85)
(Table 2). The previous skin tumour types comprised non-melanocytic skin cancer in 32 patients (78%)
and melanocytic skin cancer in nine patients (22%) (all Clark level 2). In total, nine patients were
diagnosed with more than one (two to three) additional different skin tumour types.
Discussion
Melanocytic malignancies of the skin are recorded in three different registries in Denmark: (1)
Danish Melanoma Registry administered by the Danish Melanoma Group,3 (2) Danish Cancer Registry
(DCR)16 and (3) the DPR administered by the Danish Society of Pathology.17 Whereas DCR contains
more general information (ICD-10 and tumour, node, metastasis (TNM) classiﬁcation), DMR and DPRFigure 1. Comparison of the anatomical localization of malignant melanoma in situ in age subgroups among 144 patients diagnosed
between 2012 and 2013 in Health care Region Zealand.
Table 2
Prevalence of other skin malignancies among 144 patients diagnosed with cutaneous malignant melanoma in situ.
Total Female Male p-value
Number 144 78 66
Other tumour types (no, %)
Yes (one or more) 41 (28) 23 (29) 18 (27) 0.85
No 103 (72) 55 (71) 48 (73)
Tumour types (no, %)
Non-melanoma skin cancer 32 (22) 19 (24) 13 (20) 0.55
Basal cell carcinoma 19 (13) 12 (15) 7 (11)
Square cell carcinoma 5 (3) 1 (1) 4 (6)
Actinic keratosis 7 (5) 5 (6) 2 (3)
Other 1 (1) 1 (1) 0 (0)
Melanoma skin cancer 9 (6) 4 (5) 5 (8) 0.73
Invasive cutaneous malignant
melanoma (Clark level 2)
9 (6) 4 (5) 5 (8)
Malignant melanoma in situ
(Clark level 1)
0 (0) 0 (0) 0 (0)
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data from DMR and DPR, as these two registries combined covered our requirements.
Health care Region Zealand and its inhabitants are comparable to the other four health-care regions
in Denmark, and therefore we believe that our results to a large extent are representative of the entire
population of Denmark.18 Although all treatment and diagnostics were conducted at a single institu-
tion (Roskilde University Hospital), all clinical procedures and pathological examination strictly fol-
lowed the national guidelines provided by the DanishMelanoma Group.3 This study population reﬂects
the Danish population, which is generally well educated, ethnically homogeneous (Caucasians) and
beneﬁting from a uniform public health-care system covering all citizens, and thus limiting the
generalizability to other populations with different health-care systems, demographics or treatment
protocols. We attempted to increase the completeness of our data set by validating all data which
included identifying irregularities and rectifying the data by reviewing the histological examinations
and clinical reports. However, the cross-sectional design of our study precludes conclusions on cau-
sality and analyses changes in variables over time.
The median age in our study population was 66 years. More females were diagnosed with MIS in
comparison to males, 54% versus 46%, respectively. SSM in situ accounted for 56% of the lesions, while
LM and NM (nodular melanoma) 1% accounted for 43 and 1%, respectively. We found no difference in
tumour type or tumour localization between genders. When comparing age groups (21e40, 41e60,
61e80, >80 years) to the anatomical site of the lesion, we found that tumours were more likely to be
found on the head and neck region among the oldest patients (>61 years), whereas they were more
likely to be found on the trunk among the younger patients (41e60 years, p < 0.001). Patients diag-
nosed with LM were older in comparison to those with SSM in situ (median age 71 vs. 59 years,
respectively; p < 0.001). In addition, we found that LMwas predominantly found on the head and neck
region, whereas SSM in situ was predominant on the trunk (p < 0.001). This suggests that there are two
subgroups consisting of SSM in situ and LMwith rather different patient characteristics within the MIS
population. In this study, nine (6%) patients had previously been diagnosedwithmelanoma skin cancer
(MSC), all of themwith invasive CMM. In addition, 22% of the patients had previously been diagnosed
with non-MSC (NMSC). On the basis of these results, in order to identify additional skin tumours, we
suggest that the diagnosis of MIS should lead to a thorough clinical examination of the body surface.
Compared to the 520 patients diagnosed with CMM in the same period (Reference: Accepted for
publication in Danish Medical Journal, June 2015), patients with MIS were signiﬁcantly older (CMM
median age 61 years vs. MIS median age 66 years; p < 0.01).
For both genders, MIS was predominantly located on the head and neck followed by the trunk,
whereas CMMwas predominantly located on the trunk and lower extremities (Figure 2). The difference
in anatomical localization betweenMIS and CMMwas signiﬁcant, p < 0.01. The identiﬁed differences in
anatomical distribution and in median age between MIS and CMM contradict the general assumption
thatMIS is a simple precursor of CMM. But, as described earlier, theMIS group appears to consist of two
Figure 2. Comparison of the anatomical localization of tumours in patients diagnosed with malignant melanoma in situ (144 pa-
tients) or invasive malignant melanoma (517 patients) between 2012 and 2013 in Health-care Region Zealand.
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localization predominantly on the trunk in both groups and median age 59 years vs. 61 years,
respectively). It has been shown that patients who had a primaryMIS on body sites other than the head
and neck have a signiﬁcantly higher risk of developing a subsequent primary CMM compared with
patients who had their primary MIS on the head and neck e in particular if the lesion was located on
the lower extremities.4 These observations support the fact that LM has less potential for malignant
transformation in comparison to SSM in situ, and thereby tends to weaken the general association
between MIS and CMM.
In a recently published study based on data from Danish Registry of Pathology between 1997 and
2011, Toender et al found an overall fourfold increase in the incidence rate of MIS in Denmark from 1.97
to 8.7 cases per 100,000 person years with a threefold increase among females (2.6e8.1) and a fourfoldPicture 1. An 80-year-old male was referred with a brown tumour localized on the auricular helix measuring 7  4 mm (Picture 1).
The element was treated with a wedge excision of 5-mm excision margins. The histological examination conﬁrmed the diagnosis of
lentigo maligna (LM). Although the boarders of the tumour appeared to be relatively well deﬁned, the initial excision was not radical,
and a subsequent wedge excision was done. This case report illustrates that determining the extension of LM can be challenging.
A. Klit et al. / JPRAS Open 6 (2015) 59e66 65increase among males (1.4e5.6).19 Furthermore, the highest increase was found for the latest 5-year
period (2007e2011) in the time period investigated. As this study is a cross-sectional study, we cannot
draw conclusions on incidence (see Picture 1).
In a population-based study from Sweden, they found the peak incidence rate of MIS to be at 75e84
years amongmales and 60e64 years among females. In addition, they found thatmales developMIS on
the head and neck, while the female population develop MIS at the lower extremities.17
In a recently published Australian study,4 it was found that more males in comparison to females
developed MIS (54% vs. 46%, respectively) and that more elderly people (>65 years) developed MIS.
They found an anatomical distribution for the ﬁrst MIS as follows: head 30%, trunk 28%, upper ex-
tremities 24%, lower extremities 15% and not speciﬁed 2%. MIS was found to be signiﬁcantly more likely
to appear in the head and neck region compared with CMM. All these reported ﬁndings are in line with
our results.
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